-+ 0.00%
-+ 0.00%
-+ 0.00%

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

Barchart·09/28/2026 06:30:00
Listen to the news

New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience

FDA removal of the prior drug exposure limit provides greater dosing flexibility in
future clinical trials

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.